271 related articles for article (PubMed ID: 26239045)
21. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
Yamada T; Mino Y; Naito T; Kawakami J
J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
[TBL] [Abstract][Full Text] [Related]
22. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
[TBL] [Abstract][Full Text] [Related]
23. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
24. Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.
Gong F; Hu H; Ouyang Y; Liao ZZ; Kong Y; Hu JF; He H; Zhou Y
Toxicol Appl Pharmacol; 2023 May; 466():116475. PubMed ID: 36931438
[TBL] [Abstract][Full Text] [Related]
25. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.
Bramness JG; Skurtveit S; Gulliksen M; Breilid H; Steen VM; Mørland J
Eur J Clin Pharmacol; 2005 Aug; 61(7):499-506. PubMed ID: 16021435
[TBL] [Abstract][Full Text] [Related]
26. A genetic score combining CYP450 2C19 and 3A4 genotypes to predict voriconazole plasma exposure?
Gautier-Veyret E; Fonrose X; Stanke-Labesque F
Int J Antimicrob Agents; 2016 Aug; 48(2):221-2. PubMed ID: 27318623
[No Abstract] [Full Text] [Related]
27. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
[TBL] [Abstract][Full Text] [Related]
28. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
Zhong X; Tong X; Ju Y; Du X; Li Y
Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
[TBL] [Abstract][Full Text] [Related]
29. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
[TBL] [Abstract][Full Text] [Related]
30. Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysis.
Zhang Y; Hao X; Hou K; Hu L; Shang J; He S; Yang C; Huang L; Feng Y
Pharmacogenet Genomics; 2022 Sep; 32(7):257-267. PubMed ID: 35947050
[TBL] [Abstract][Full Text] [Related]
31. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.
Zubiaur P; Kneller LA; Ochoa D; Mejía G; Saiz-Rodríguez M; Borobia AM; Koller D; García IG; Navares-Gómez M; Hempel G; Abad-Santos F
Clin Pharmacokinet; 2021 Feb; 60(2):261-270. PubMed ID: 32939689
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
[TBL] [Abstract][Full Text] [Related]
34. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.
Huang X; Zhou Y; Zhang J; Xiang H; Mei H; Liu L; Tong L; Zeng F; Huang Y; Zhou H; Zhang Y
Br J Clin Pharmacol; 2022 Oct; 88(10):4515-4525. PubMed ID: 35508605
[TBL] [Abstract][Full Text] [Related]
35. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.
Li X; Yu C; Wang T; Chen K; Zhai S; Tang H
Eur J Clin Pharmacol; 2016 Oct; 72(10):1185-1193. PubMed ID: 27388292
[TBL] [Abstract][Full Text] [Related]
36. Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers.
Huppertz A; Ott C; Bruckner T; Foerster KI; Burhenne J; Weiss J; Zorn M; Haefeli WE; Czock D
Clin Pharmacol Ther; 2019 Dec; 106(6):1290-1298. PubMed ID: 31152598
[TBL] [Abstract][Full Text] [Related]
37. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
Kobayashi M; Kajiwara M; Hasegawa S
J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
Hu L; Huang Q; Huang S; Feng Z
Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
[TBL] [Abstract][Full Text] [Related]
39. Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers.
Lee SW; Oh J; Kim AH; Ji SC; Park SI; Yoon SH; Chung JY; Yu KS; Jang IJ; Lee S
Pharmacogenomics J; 2020 Dec; 20(6):792-800. PubMed ID: 32461666
[TBL] [Abstract][Full Text] [Related]
40. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]